Clinical Trial: Assess the Safety, Tolerability, and Pharmacokinetics of HL-1186 in Healthy Participants

U.S., April 5 -- ClinicalTrials.gov registry received information related to the study (NCT06912295) titled 'Assess the Safety, Tolerability, and Pharmacokinetics of HL-1186 in Healthy Participants' on March 24.

Brief Summary: This single-center, randomized, double-blind, placebo-controlled, two-part study is designed to assess the safety, tolerability and PK of oral HL-1186 Tablet in healthy participants.

Study Start Date: March 21

Study Type: INTERVENTIONAL

Condition: Healthy Participants

Intervention: DRUG: HL-1186

HL-1186 tablet for oral administration.

DRUG: HL-1186 placebo

HL-1186 placebo tablet for oral administration.

Recruitment Status: RECRUITING

Sponsor: Shanghai Huilun Pharmaceutical Co., Ltd.

Published by HT Digita...